High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex.

ABSTRACT: After initially successful treatment of infantile spasms, the long-term cumulative risk of relapse approaches 50%, and there is no established protocol to mitigate this risk. Although vigabatrin may be an effective means to prevent relapse, there is little guidance as to ideal duration and dosage. Using a cohort of children with infantile spasms and tuberous sclerosis complex (TSC), we evaluated the potential association of post-response VGB treatment and the rate of infantile spasms relapse. Patients with infantile spasms and clinical response to vigabatrin were identified among a multicenter prospective observational cohort of children with TSC. For each patient we recorded dates of infantile spasms onset, response to vigabatrin, relapse (if any), and quantified duration and dosage of vi

SUBMITTER: Hussain SA 

PROVIDER: S-EPMC6347124 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature